Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group  by Takenaka, Katsuto et al.
Biol Blood Marrow Transplant 21 (2015) 2008e2016Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgCytomegalovirus Reactivation after Allogeneic Hematopoietic
Stem Cell Transplantation is Associated with a Reduced Risk of
Relapse in Patients with Acute Myeloid Leukemia Who
Survived to Day 100 after Transplantation: The Japan Society
for Hematopoietic Cell Transplantation
Transplantation-related Complication Working GroupKatsuto Takenaka 1,*, Tetsuya Nishida 2, Yuki Asano-Mori 3, Kumi Oshima 4, Kazuteru Ohashi 5,
Takehiko Mori 6, Heiwa Kanamori 7, Koichi Miyamura 8, Chiaki Kato 9, Naoki Kobayashi 10,
Naoyuki Uchida 3, Hirohisa Nakamae 11, Tatsuo Ichinohe 4, Yasuo Morishima 12, Ritsuro Suzuki 13,
Takuhiro Yamaguchi 14, Takahiro Fukuda 15
1Department of Hematology and Oncology, Kyushu University Hospital, Fukuoka, Japan
2Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
3Department of Hematology, Toranomon Hospital, Tokyo, Japan
4Department of Hematology and Oncology, Hiroshima University Research Institute for Radiation Biology and Medicine, Hiroshima, Japan
5Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
6Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
7Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
8Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
9Department of Hematology, Meitetsu Hospital, Nagoya, Japan
10Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan
11Department of Hematology, Osaka City University Hospital, Osaka, Japan
12Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
13Department of Hematopoietic Stem Cell Transplantation Data Management and Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan
14Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan
15Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, JapanArticle history:
Received 11 May 2015
Accepted 20 July 2015
Key Words:
Cytomegalovirus
Allogeneic hematopoietic stem
cell transplantation
Risk of relapse
Nonrelapse mortalityFinancial disclosure: See Acknowl
* Correspondence and reprint
Department of Hematology and On
1, Maidashi, Higashi-ku, Fukuoka 8
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
Cytomegalovirus (CMV) infection is a major infectious complication after allogeneic hematopoietic cell
transplantation (allo-HSCT). Recently, it was reported that CMV reactivation is associated with a decreased
risk of relapse in patients with acute myeloid leukemia (AML). The aim of this study was to evaluate the
impact of early CMV reactivation on the incidence of disease relapse after allo-HSCT in a large cohort of
patients. The Japan Society for Hematopoietic Cell Transplantation’s Transplantation-Related Complication
Working Group retrospectively surveyed the database of the Transplant Registry Uniﬁed Management Pro-
gram at the Japan Society for Hematopoietic Cell Transplantation. Patients with AML (n ¼ 1836), acute
lymphoblastic leukemia (ALL, n ¼ 911), chronic myeloid leukemia (CML, n ¼ 223), and myelodysplastic
syndrome (MDS, n ¼ 569) who underwent their ﬁrst allo-HSCT from HLA-matched related or unrelated
donors between 2000 and 2009 and who survived without disease relapse until day 100 after transplantation
were analyzed. Patients who received umbilical cord blood transplantation were not included. Patients un-
derwent surveillance by pp65 antigenemia from the time of engraftment, and the beginning of preemptive
therapy was deﬁned as CMV reactivation. Cox proportional hazards models were used to evaluate the risk
factors of relapse, nonrelapse, and overall mortality. CMV reactivation and acute/chronic graft-versus-host
disease (GVHD) were evaluated as time-dependent covariates. CMV reactivation was associated with a
decreased incidence of relapse in patients with AML (20.3% versus 26.4%, P ¼ .027), but not in patients withedgments on page 2016.
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K. Takenaka et al. / Biol Blood Marrow Transplant 21 (2015) 2008e2016 2009ALL, CML, or MDS. Among 1836 patients with AML, CMV reactivation occurred in 795 patients (43.3%) at a
median of 42 days, and 436 patients (23.7%) relapsed at a median of 221 days after allo-HSCT. Acute GVHD
grades II to IV developed in 630 patients (34.3%). By multivariate analysis considering competing risk factors,
3 factors were signiﬁcantly associated with a decreased risk of AML relapse and 1 factor with an increased risk
of AML relapse: CMV reactivation (hazard ratio [HR], .77; 95% conﬁdence interval [CI], .59 to .99), unrelated
donor compared with related donor (HR, .59; 95% CI, .42 to .84), development of chronic GVHD (HR, .77; 95%
CI, .60 to .99), and pretransplantation advanced disease status compared with standard disease status (HR,
1.99; 95% CI, 1.56 to 2.52). However, CMV reactivation was associated with increased nonrelapse mortality
(HR, 1.60; 95% CI, 1.18 to 2.17) and overall mortality (HR, 1.37; 95% CI, 1.11 to 1.69). A beneﬁcial effect of CMV
reactivation on subsequent risk of relapse was observed in patients with AML but not in those with other
hematological malignancies. However, this beneﬁt was nulliﬁed by the increased nonrelapse mortality. The
underlying mechanism is unclear; however, immunological activation against CMV reactivation plays an
essential role in this association. Thus, immune augmentation treatment options, including vaccination and
adoptive T cell transfer, may be useful to take advantage of the efﬁcacy of CMV reactivation with minimal
increase in nonrelapse mortality.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION Because of conﬂicting results, we aimed to evaluate the
Cytomegalovirus (CMV) infection is a major infectious
complication after allogeneic hematopoietic stem cell
transplantation (allo-HSCT). CMV multiorgan disease is a
signiﬁcant cause of morbidity and mortality after allo-HSCT
despite advances in the treatment of CMV disease using
ganciclovir (GCV) and/or foscarnet (FCV) [1-5]. Current
strategies to manage CMV infection by early detection of
CMV reactivation and the use of preemptive antiviral therapy
are highly effective for decreasing the incidence of CMV end-
organ disease within the ﬁrst 100 days after allo-HSCT to
<10% [5-7]. However, up to 80% of patients develop CMV
reactivation after allo-HSCT. CMV reactivation and subse-
quent antiviral therapy often result in an increased risk of
acute graft-versus-host disease (GVHD) and infectious com-
plications because of drug-inducedmyelosuppression [1,2,8].
Thus, the clinical impact on the prognosis of asymptomatic
CMV reactivation early after allo-HCT is controversial.
The beneﬁcial effect of CMV infection on disease relapse
was ﬁrst suggested almost 3 decades ago. Lönnqvist et al.
observed that leukemia relapse after allo-HSCT was less
frequent in patients with CMV infection compared with
those without CMV infection in a small cohort of patients [9].
However, the results from subsequent studies analyzing the
association between the pretransplantation CMV donor and
recipient serostatus and risk of relapse in larger cohorts were
controversial [10-15]. More recently, Elmaagacli et al. sug-
gested that CMV reactivation after allo-HSCT is associated
with a reduced risk of relapse in adult patients with acute
myeloid leukemia (AML), independent of GVHD, who
underwent allo-HSCT from fully matched donors with
myeloablative (MA) conditioning, resulting in improved
event-free survival and overall survival (OS) [16]. Subse-
quently, in a large cohort of patients, Green et al. found only a
modest protective effect of CMV reactivation on relapse in
patients with AML after allo-HSCT without any beneﬁt in OS
because of increased nonrelapse mortality (NRM) [17].
Several groups have suggested a similar association in a
cohort of patients with AML or chronic myeloid leukemia
(CML) [18,19]. In contrast, a protective effect of CMV reac-
tivation on reducing relapse is not evident in patients with
acute lymphoblastic leukemia (ALL) [17], lymphoma [17,20],
myelodysplastic syndrome (MDS) [7], and pediatric acute
leukemia [21]. In addition, some groups suggested that this
protective effect is inﬂuenced by conditioning regimen and is
restricted to patients receiving MA conditioning [22].beneﬁcial impact of CMV reactivation early after allo-HSCT
on the risk of disease relapse in patients with hematologi-
cal malignances undergoing HLA matched allo-HSCT in a
larger cohort of patients.
PATIENTS AND METHODS
Patients
We included patients with AML, ALL, MDS, or CML ages at least 16 years
who underwent a ﬁrst allo-HSCT from serologically HLA-A, -B, and -DR 6/
6ematched related or allele 6/6ematched unrelated donors between 2000
and 2009 and who survived without disease relapse until day 100 after allo-
HSCT. Bone marrow and peripheral blood stem cells were used as stem cell
sources. Clinical data for these patients were obtained from the Japan
Transplant Outcome Registry Database and conﬁrmed by the Transplant
Registry Uniﬁed Management Program in 2010 [23]. We excluded patients
who received cord blood transplantation, those who received prophylactic
GCV or FCV after allo-HSCT, and those who received ex vivo or in vivo T cell
depletion, such as antithymocyte globulin or alemtuzumab. This study was
approved by the Data Management Committee of the Japan Society for
Hematopoietic Cell Transplantation and by the ethical committee of the
Kyushu University School of Medicine.
Deﬁnitions
Patients underwent surveillance of pp65 antigenemia from the time of
engraftment after allo-HSCT. CMV reactivationwas deﬁned as the beginning
of CMV preemptive therapy. Intravenous GCV or FCV was provided as CMV
preemptive therapy according to the protocol of each transplantation center.
Preemptive therapy was generally initiated when at least 2 CMV pp65
antigenepositive cells per 50,000 white blood cells were detected. CMV
disease was diagnosed according to published recommendations [24].
Acute and chronic GVHD were diagnosed and graded according to
established criteria [25,26]. Conditioning regimens were classiﬁed as MA if
total body irradiation >8 Gy, oral busulfan 9 mg/kg, intravenous busulfan
7.2 mg/kg, or melphalan >140 mg/m2 were included in the conditioning
regimens; in contrast, regimens were classiﬁed as nonmyeloablative regi-
mens based on the report by the Center for International Blood and Marrow
Transplant Research [27].
AML and ALL in the ﬁrst or second remission, CML in the ﬁrst or second
chronic phase, and MDS with refractory anemia with or without ringed
sideroblasts were deﬁned as standard-risk diseases, and other malignant
diseases were deﬁned as advanced-risk diseases.
Endpoints
The primary endpoint was the cumulative incidence of disease relapse
stratiﬁed by CMV reactivation. Secondary endpoints included the incidence
of CMV reactivation, relapse, OS, and NRM.
Statistical Analysis
In this study, we limited the analysis to patients who survived without
disease relapse until day 100 after allo-HSCT because early death and dis-
ease relapse before day 100 were greatly inﬂuenced by regimen-related
toxicities and pretransplantation disease status. Univariate probabilities of
CMV reactivation, acute and chronic GVHD, relapse, and NRM were
K. Takenaka et al. / Biol Blood Marrow Transplant 21 (2015) 2008e20162010estimated on the basis of cumulative incidence curves. The probability of OS
was estimated according to the Kaplan-Meier method and compared using
the log-rank test. In Cox proportional hazards models, CMV reactivation and
acute/chronic GVHD were evaluated as time-dependent covariates. When
CMV reactivation and acute/chronic GVHD occurred before disease relapse,
regardless of when they occurred, these were considered for the risk of
disease relapse in the analysis. Events of relapse and NRM were treated as
competing events. Incidence data regarding relapse and NRM were
compared using the Gray’s test [28]. Competing risk regression analysis was
used to identify factors associated with relapse, NRM, and OS in multivariate
analysis [29]. Statistical signiﬁcancewas deﬁned as P< .05. All analyses were
performed using Stata version 12.0 (StataCorp, College Station, TX), EZR on
R commander (R version 2.13.0.; Saitama Medical Center, Jichi Medical
University, Saitama, Japan) [30], and Statistical Analysis Software procedures
(SAS version 9.4).
RESULTS
Patient Characteristics
Initially, 5632 patients were eligible for this study. How-
ever, there were 940 patients who did not survive until day
100 without relapse and were not eligible for this study: 171
patients did not achieve engraftment, 186 patients did not
achieve complete remission after transplantation, 197 pa-
tients died without relapse, and 386 patients relapsed by day
100. Among the 5632 patients, we excluded 2093 patients
who lacked data on survival status, relapse, and CMVTable 1
Patient Characteristics according to Disease Group
Characteristic All Patients AML
No. of patients 3539 1836
Patient age
Median (range) 43 (16-74) 46 (16-74)
<50 1883 (53%) 1090 (58%)
50 1656 (47%) 746 (42%)
Patient sex
Male 2082 (59%) 1074 (58%)
Female 1457 (41%) 762 (42%)
Donor type
Related BM 924 (26%) 420 (23%)
Related PBSC 1006 (28%) 569 (31%)
Unrelated BM 1609 (45%) 847 (46%)
Recipient/donor CMV serology
Negative/negative 243 (7%) 131 (7%)
Negative/positive 313 (9%) 142 (8%)
Positive/negative 481 (14%) 232 (13%)
Positive/positive 1909 (54%) 1028 (56%)
Not available 593 (17%) 303 (17%)
Disease status
Standard 2442 (69%) 1233 (67%)
Advanced 1082 (31%) 597 (33%)
Not available 15 (0%) 6 (0%)
Performance status
0-1 3355 (95%) 1736 (95%)
2-4 162 (5%) 90 (5%)
Not available 22 (0%) 10 (1%)
Preparative regimen
MA 2726 (78%) 1381 (75%)
Nonmyeloablative 791 (23%) 446 (24%)
Not available 22 (1%) 9 (1%)
GVHD prophylaxis
CSP-based 2122 (60%) 1088 (59%)
FK506-based 1363 (39%) 717 (39%)
Not available 54 (2%) 31 (2%)
Acute GVHD
Grade 0-1 2272 (64%) 1190 (65%)
Grade 2-4 1242 (35%) 630 (34%)
Not available 25 (1%) 16 (1%)
Chronic GVHD
None 1860 (53%) 955 (52%)
Limited/extensive 1545 (44%) 814 (44%)
Not available 126 (4%) 67 (4%)
BM indicates bone marrow; PBSC, peripheral blood stem cells; CSP, cyclosporine;
Data presented are n (%), unless otherwise indicated.infection. Eventually, a total of 3539 patients were included
in this study: 1836 with AML, 911 with ALL, 223 with CML,
and 569 with MDS. Patient, disease, and transplantation
characteristics are summarized in Table 1. Donor CMV sero-
negativity (D-CMV)/recipient CMV seronegativity (R-
CMV) was recorded in 243 cases (7%), and in 2703 cases
(77%), D-CMVþ and/or R-CMVþ was present. Complete data
on CMV serostatus was unavailable for 593 cases (17%).
Median age was 43 years (range, 16 to 74 years). Approxi-
mately one half of the patients (54%) received transplants
from HLA-matched related donors and the remaining pa-
tients (45%) received transplants from HLA-matched unre-
lated donors. The median follow-up duration was 773 days
and the 5-year OS was 59% in the combined cohort.CMV Reactivation after allo-HSCT
Patients underwent surveillance of pp65 antigenemia
from the time of engraftment. CMV reactivation was
observed in 1518 patients (43.3%) a median of 42 days after
transplantation (range, 3 to 767 days) in the combined
cohort. Among 1518 patients, 1454 (95.7%) received CMV-
preemptive therapy within 100 days of transplantation.
Patient and transplantation characteristics based on post-ALL CML MDS
911 223 569
37 (16-68) 38 (16-68) 51 (16-70)
526 (59%) 123 (55%) 144 (25%)
385 (41%) 100 (45%) 425 (75%)
513 (56%) 145 (65%) 350 (62%)
398 (44%) 78 (35%) 219 (38%)
266 (29%) 68 (30%) 170 (30%)
222 (24%) 66 (30%) 149 (26%)
423 (46%) 89 (40%) 250 (44%)
74 (8%) 11 (5%) 27 (5%)
113 (12%) 22 (10%) 36 (6%)
133 (15%) 31 (14%) 85 (15%)
450 (49%) 104 (47%) 327 (58%)
141 (16%) 55 (25%) 94 (17%)
798 (88%) 157 (70%) 254 (45%)
112 (12%) 64 (29%) 309 (54%)
1 (0%) 2 (1%) 6 (1%)
877 (96%) 212 (95%) 530 (93%)
29 (3%) 7 (3%) 36 (6%)
5 (1%) 4 (2%) 3 (1%)
799 (88%) 193 (87%) 353 (62%)
107 (12%) 27 (12%) 211 (37%)
5 (0%) 3 (1%) 5 (1%)
552 (61%) 155 (70%) 327 (58%)
345 (38%) 65 (29%) 236 (42%)
14 (2%) 3 (1%) 6 (1%)
591 (65%) 136 (61%) 355 (62%)
316 (35%) 87 (39%) 209 (37%)
4 (0%) 0 (0%) 5 (1%)
514 (56%) 102 (46%) 289 (51%)
359 (39%) 113 (51%) 259 (46%)
38 (4%) 0 (0%) 21 (4%)
FK506, tacrolimus.
Table 3
Variables Inﬂuencing Post-Transplantation CMV Reactivation inMultivariate
Analysis
Parameter HR (95%CI) P Value
Age >50 yr 1.40 (1.24-1.58) <.01
Female donor to male recipient
versus other combination
.91 (.80-1.04) NS
Unrelated versus related donor 1.38 (1.17-1.62) .01
PBSC versus BM graft .90 (.76-1.06) NS
R-CMV/D-CMVþ versus R-CMV/D-CMV .96 (.69-1.34) NS
R-CMVþ/D-CMV versus R-CMV/D-CMV 2.15 (1.62-2.87) <.01
R-CMVþ/D-CMVþ versus R-CMV/D-CMV 1.92 (1.48-2.49) <.01
Disease status advanced versus standard 1.08 (.96-.121) NS
Performance status 2 to 4 1.00 (.79-1.26) NS
Preparative regimens NMA versus MA .92 (.80-1.06) NS
GVHD prophylaxis FK506-based
versus CSP-based
1.10 (.95-1.25) NS
Acute GVHD grades II to IV 2.35 (2.10-2.63) <.01
NMA indicates nonmyeloablative.
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Table 2. Patients with and without CMV reactivation were
similar in regard to disease types. CMV reactivation devel-
oped more frequently in older patients, in those who had a
positive donor or recipient CMV serostatus (P < .001), in
those undergoing transplantation from an unrelated donor
(P < .001), and in those who had grades II to IV acute GVHD
(P < .001). Grades II to IV acute GVHD developed in 1242
patients (35%) a median of 29 days after transplantation
(range, 4 to 136 days). Of the 766 patients with grades II to
IV acute GVHD with CMV reactivation, acute GVHD was
diagnosed a median of 17 days earlier (range, 1 to 736 days)
than the development of CMV reactivation in 596 patients
(78%). In the multivariate models, older patient age, unre-
lated donor transplantations, R-CMVþ, and acute GVHD
grades II to IV were associated with the development of
CMV reactivation (Table 3). D-CMVþ did not increase the
incidence of CMV reactivation when recipients were
CMV-seronegative.Table 2
Patient Characteristics according to Post-transplantation CMV Reactivation
Characteristic All Patients Patients
without CMV
Reactivation
Patients
with CMV
Reactivation
P
Value
No. of patients 3539 2021 (57%) 1518 (43%)
Patient age
Median (range) 43 (16-74) 40 (16-72) 47 (16-74)
<50 1883 (53%) 1197 (60%) 686 (44%) <.01
50 1656 (47%) 794 (40%) 862 (56%)
Patient sex
Male 2082 (59%) 1165 (59%) 917 (59%) NS
Female 1457 (41%) 826 (41%) 631 (41%)
Donor type
Related 1930 (55%) 1215 (61%) 715 (46%) <.01
Unrelated 1609 (46%) 776 (39%) 833 (54%)
Donor/recipient sex
Female/male 812 (23%) 466 (23%) 346 (23%) NS
Other combinations 2706 (77%) 1518 (77%) 1188 (77%)
Stem cell source
BM 2533 (72%) 1352 (68%) 1181 (76%) <.01
PB 1006 (28%) 639 (32%) 367 (24%)
Recipient/donor CMV serology
Negative/negative 243 (8%) 175 (11%) 68 (5%) <.01
Negative/positive 313 (11%) 230 (14%) 83 (6%)
Positive/negative 481 (16%) 228 (14%) 253 (19%)
Positive/positive 1909 (65%) 993 (61%) 916 (69%)
Negative/negative 243 (8%) 175 (11%) 68 (5%) <.01
Other combinations 2703 (92%) 1451 (89%) 1252 (95%)
Disease type
AML 1836 (52%) 1041 (52%) 795 (51%) NS
ALL 911 (26%) 533 (27%) 378 (24%)
CML 223 (6%) 134 (7%) 89 (6%)
MDS 569 (16%) 283 (14%) 286 (19%)
Disease status
Standard 2442 (69%) 1432 (72%) 1010 (66%) <.01
Advanced 1082 (31%) 554 (28%) 528 (34%)
Performance status
0-1 3355 (95%) 1901 (96%) 1454 (95%) NS
2-4 162 (5%) 80 (4%) 82 (5%)
Preparative regimens
MA 2726 (78%) 1561 (79%) 1165 (76%) .01
Nonmyeloablative 791 (23%) 413 (21%) 378 (25%)
GVHD prophylaxis
CSP-based 2122 (61%) 1279 (65%) 843 (55%) <.01
FK506-based 1363 (39%) 682 (35%) 681 (45%)
Acute GVHD
Grade 0-1 2272 (65%) 1525 (77%) 745 (49%) <.01
Grade 2-4 1242 (35%) 455 (23%) 787 (51%)
NS indicates not signiﬁcant; PB, peripheral blood.
Data presented are n (%), unless otherwise indicated.CMV Reactivation and Risk of Relapse after allo-HSCT in
the Combined Cohort
In the combined cohort of 3539 patients, 778 patients
(22.0%) relapsed at a median of 242 days (range, 101 to
2057 days). In the univariate regression model, the incidence
of relapse among patients with CMV reactivation was
signiﬁcantly lower than in those without CMV reactivation
(20.3% versus 26.1%, P< .01). In time-dependent multivariate
analysis, pretransplantation disease status was a main co-
variate increasing the risk of relapse in any disease group,
and the main variables associated with a decreased risk of
relapse included the following: receiving transplants from
unrelated donors, having post-transplantation CMV reac-
tivation, and having chronic GVHD in the combined cohort
(Table 4). Development of chronic GVHD was the main var-
iable affecting the relapse risk. Post-transplantation CMV
reactivation was 1 of the independent protective factors for
the risk of relapse (adjusted hazard ratio [HR], .82; 95%
conﬁdence interval [CI], .68 to .98; P ¼ .03). CMV disease
developed in 139 patients in the combined cohort of 3539
patients. The incidence of relapse among patients with CMV
disease was equivalent to that in patients without CMV dis-
ease (20.1% versus 22.0%, P ¼ .607), indicating that the
development of CMV disease does not inﬂuence the inci-
dence of relapse.
Although pretransplantation CMV seropositivity was
associated with increased incidence of CMV reactivation, it
was an independent risk factor for relapse in the combined
cohort (R-CMVþ and/or D-CMVþ versus R-CMV/D-CMV;
adjusted HR, 1.65; 95% CI, 1.14 to 2.37; P ¼ .01). This was not
evident in patients within the individual disease groups. In
the combined cohort, compared with R-CMV/D-CMV, the
adjusted HR for R-CMVþ/D-CMVþ was 1.70 (95% CI, 1.17 to
2.47; P < .01), whereas the adjusted HRs for R-CMV/D-
CMVþ and R-CMVþ/D-CMV were 1.50 (95% CI, .97 to 2.33;
P ¼ .69) and 1.39 (95% CI, .91 to 2.14; P ¼ .13), respectively,
indicating that R-CMVþ/D-CMVþwas the main risk factor for
relapse as far as pretransplantation CMV serostatus. How-
ever, an increased protective effect from relapse was
observed in CMV seropositive (R-CMVþ and/or D-CMVþ)
transplantations when CMV reactivation developed (20.6%
versus 27.1%, P < .01) compared with CMV seronegative (R-
CMV/D-CMV) transplantations with CMV reactivation
(15.9% versus 19.1%, P ¼ .74).
Table 4
Variables Inﬂuencing the Risk of Relapse in Multivariate Analysis
Parameter Combined (n ¼ 3539) AML (n ¼ 1836) ALL (n ¼ 911) CML (n ¼ 223) MDS (n ¼ 569)
HR (95% CI) P
Value
HR (95% CI) P
Value
HR (95% CI) P
Value
HR (95% CI) P
Value
HR (95% CI) P
Value
Age >50 yr 1.04 (.85-1.27) NS 1.14 (.86-1.52) NS .92 (.64-1.32) NS .44 (.16-1.24) NS 4.08 (1.40-11.86) .01
Disease status advanced
versus standard
2.22 (1.84-2.68) <.01 1.99 (1.56-2.52) <.01 2.54 (1.71-3.77) <.01 1.71 (.65-4.50) NS 3.65 (1.87-7.15) <.01
Unrelated versus
related donor
.63 (.49-.81) <.01 .59 (.42-.84) <.01 .67 (.43-1.04) NS .96 (.26-3.56) NS .62 (.30-1.29) NS
R-CMVþ and/or D-CMVþ
versus R-CMV/D-CMV
1.65 (1.14-2.37) .01 1.36 (.86-2.14) NS 1.72 (.93-3.20) NS - NS - NS
CMV reactivation .82 (.68-.98) .03 .77 (.59-.99) .04 .90 (.63-1.25) NS 1.51 (.56-4.06) NS .70 (.40-1.23) NS
Acute GVHD grades II to IV .82 (.68-1.00) NS 1.01 (.78-1.30) NS .70 (.49-.99) .04 .52 (.16-1.62) NS .58 (.30-1.13) NS
Chronic GVHD .76 (.63-.92) <.01 .77 (.60-.99) .04 .85 (.60-1.19) NS .21 (.07-.65) .01 .68 (.39-1.21) NS
“-” indicates not applicable.
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tivationeassociated protective effect on relapse may be
mediated by GCV-associated myelosuppression. Although
the information regarding the laboratory data during CMV
treatment was limited in our registry data, there was no
signiﬁcant difference in duration of preemptive therapy be-
tween relapsed and nonrelapsed patients (a median of
25.5 days and 29.5 days, respectively [P ¼ .285]).CMV Reactivation and NRM and OS in the Combined
Cohort
The 5-year NRM was 20.6% (95% CI, 18.9 to 22.3) in the
combined cohort. CMV reactivation was an independent risk
factor for the 5-year NRM (adjusted HR, 1.66; 95% CI, 1.34 to
2.06; P < .01) (Supplementary Figure 1, Table 5). In addition,
older age, pretransplantation disease status, unrelated donor
transplantations, acute GVHD grades II to IV, and chronic
GVHD were associated with increased NRM in the combined
cohort. CMV reactivation was not signiﬁcantly associated
with an increased NRM in patients with CML and MDS. In
addition to main covariates for the increased overall mor-
tality, such as disease relapse, pretransplantation disease
status, and acute GVHD grades II to IV, CMV reactivation was
an independent risk factor for overall mortality at 5 years
(adjusted HR, 1.30; 95% CI, 1.11 to 1.51; P< .01) because of the
increased NRM associated with CMV reactivation (Figure 1,
Table 6). Pretransplantation CMV serostatus was not signif-
icantly associated with a different OS rate. Thus, the advan-
tages of the decreased risk of relapse among patients with
post-transplantation CMV reactivation were offset by
increased NRM, causing a decrease in OS.Table 5
Variables Inﬂuencing NRM in Multivariate Analysis
Parameter Combined (n ¼ 3539) AML (n ¼ 1836) A
HR (95% CI) P
Value
HR (95% CI) P
Value
H
Age >50 yr 1.80 (1.42-2.30) <.01 1.80 (1.28-2.55) <.01 1
Disease status advanced
versus standard
1.32 (1.06-1.64) .01 1.54 (1.15-2.06) <.01 1
Unrelated versus
related donor
1.56 (1.12-2.18) .01 1.48 (.93-2.34) NS 1
R-CMVþ and/or D-CMVþ
versus R-CMV/D-CMV
.66 (.46-.93) .02 .60 (.38-.96) .03
CMV reactivation 1.66 (1.34-2.06) <.01 1.60 (1.18-2.17) <.01 1
Acute GVHD grades II to IV 1.36 (1.08-1.87) .01 1.24 (.91-1.70) NS 1
Chronic GVHD 1.57 (1.27-1.94) <.01 1.62 (1.21-2.16) <.01 1CMV Reactivationeassociated Protective Effects on
Disease Relapse in Patients with AML
The cumulative incidence of relapse at 5 years was
higher for patients with AML (26.5%; 95% CI, 24.2 to 28.9)
and ALL (27.4%; 95% CI, 24.1 to 30.8). Relapse was less
common in patients with CML (13.7%; 95% CI, 9.2 to 19.1)
and MDS (12.7%; 95% CI, 9.9 to 15.8). In a univariate anal-
ysis by disease type, the incidence of relapse among pa-
tients with CMV reactivation was signiﬁcantly lower than
in those without CMV reactivation in patients with AML
(22.4% versus 29.6%, P < .01) and in those with MDS (9.4%
versus 16.3%, P < .05) (Figure 2). However, CMV reac-
tivation was not signiﬁcantly associated with a decreased
risk of relapse in patients with ALL (25.8% versus 28.4%,
P ¼ .463) or in those with CML (14.9% versus 13.5%,
P ¼ .968). In time-dependent multivariate analysis by dis-
ease type, post-transplantation CMV reactivation was 1 of
the independent protective factors for the risk of relapse
only in patients with AML (adjusted HR, .77; 95% CI, .59 to
.99; P ¼ .04). However, this beneﬁcial effect was not
evident in patients with ALL, CML, or MDS in multivariate
analysis, although there was a trend toward a reduced risk
of relapse in MDS patients (adjusted HR, .70; 95% CI, .40 to
.23; P ¼ .21).
Further, we examined if this CMV reac-
tivationeassociated protective effect was enriched in any
speciﬁc AML subpopulations, such as pretransplantation
disease status or morphological and genetic subtypes. In
the analysis by pretransplantation disease status, the CMV-
associated protective effect was observed in both patients
with standard-risk (18.2% versus 24.0%, P ¼ .048) and
advanced-risk disease (28.3% versus 43.2%, P < .001);LL (n ¼ 911) CML (n ¼ 223) MDS (n ¼ 569)
R (95% CI) P
Value
HR (95% CI) P
Value
HR (95% CI) P
Value
.52 (.93-2.50) NS 4.04 (1.81-9.01) <.01 2.13 (1.12-4.07) .02
.48 (.83-2.65) NS .78 (.33-1.83) NS .96 (.62-1.50) NS
.50 (.73-3.06) NS 1.79 (.57-5.64) NS 1.51 (.77-2.96) NS
.81 (.38-1.70) NS - NS - NS
.74 (1.09-2.75) .02 1.55 (.68-3.51) NS 1.39 (.88-2.19) NS
.35 (.83-2.19) NS 1.35 (.54-3.42) NS 1.86 (1.14-3.03) .01
.34 (.84-2.12) NS 3.55 (1.54-8.16) <.01 1.43 (.90-2.28) NS
Figure 1. Overall survival (OS) estimates stratiﬁed by post-transplantation CMV reactivation. OS estimates and 95% CI 5 years after allo-HSCT in the combined cohort
and in each disease group are shown. OS estimates were compared using the log-rank test.
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patients with advanced-risk disease than in those with
standard-risk disease (P < .001; Supplementary Figure 2).
This protective effect was independent of enriched
morphological and genetic AML subpopulations (data not
shown). Although post-transplantation CMV reactivation
was associated with a reduced risk of relapse in patients
with AML, CMV reactivation was an independent risk fac-
tor for the 5-year NRM (adjusted HR, 1.60; 95% CI, 1.18 to
2.17; P < .01; Supplementary Figure 1, Table 5), as observed
in the combined cohort, translating into higher overall
mortality at 5 years, even in patients with AML (adjusted
HR 1.37; 95% CI, 1.11 to 1.69; P < .01; Figure 2, Table 6).Table 6
Variables Inﬂuencing Overall Mortality in Multivariate Analysis
Parameter Combined (n ¼ 3539) AML (n ¼ 1836) A
HR (95% CI) P
Value
HR (95% CI) P
Value
H
Age >50 yr 1.57 (1.33-1.86) <.01 1.63 (1.29-2.06) <.01 1
Disease status advanced
versus standard
1.41 (1.20-1.65) <.01 1.56 (1.28-1.92) <.01 1
Unrelated versus
related donor
1.55 (1.24-1.95) <.01 1.35 (1.00-1.83) NS 1
R-CMVþ and/or D-CMVþ
versus R-CMV/D-CMV
.95 (.72-1.26) NS .98 (.68-1.41) NS 1
CMV reactivation 1.30 (1.11-1.51) <.01 1.37 (1.11-1.69) <.01 1
Acute GVHD grades II to IV 1.44 (1.24-1.68) <.01 1.31 (1.06-1.61) .01 1
Chronic GVHD 1.15 (.99-1.34) NS 1.13 (.92-1.39) NS 1
Relapse 12.1 (10.4-14.1) <.01 11.6 (9.50-14.3) <.01 1DISCUSSION
In this retrospective analysis using a large cohort of allo-
HSCT recipients, our data indicate that post-transplantation
CMV reactivation is associated with a reduced risk of dis-
ease relapse, independent of acute and/or chronic GVHD, in
the combined cohort and in patients with AML who survived
to day 100. Besides CMV reactivation, numerous covariates
regarding patient characteristics, HLA parity, pre-
transplantation disease status, transplantation procedures,
pretransplantation CMV serostatus, and acute and/or chronic
GVHD had to be considered as covariates that potentially
inﬂuence the risk of relapse, but CMV reactivation was an
independent predictor for disease relapse in multivariateLL (n ¼ 911) CML (n ¼ 223) MDS (n ¼ 569)
R (95% CI) P
Value
HR (95% CI) P
Value
HR (95% CI) P
Value
.43 (1.03-1.97) .03 2.46 (1.28-4.73) .01 1.96 (1.04-3.69) .04
.58 (1.10-2.29) .01 1.41 (.70-2.86) NS 1.02 (.66-1.57) NS
.62 (1.04-2.52) .03 2.08 (.74-5.86) NS 1.84 (.96-3.52) NS
.06 (.61-1.82) NS - NS .37 (.16-.83) .02
.15 (.85-1.56) NS 1.35 (.67-2.72) NS 1.34 (.89-2.02) NS
.58 (1.17-2.13) <.01 1.95 (.96-3.96) NS 2.06 (1.34-3.18) <.01
.06 (.78-1.44) NS 2.80 (1.37-5.76) .01 1.04 (.69-1.57) NS
4.0 (10.2-19.1) <.01 14.4 (5.70-36.3) <.01 13.6 (8.70-21.2) <.01
Figure 2. Cumulative incidence of relapse (CIR) stratiﬁed by post-transplantation CMV reactivation. Cumulative incidence of relapse estimates and 95% CI 5 years
after allo-HSCT in the combined cohort and in each disease group are shown. Data regarding incidence of relapse were compared using the Gray’s test.
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and relapse by day 100; 454 patients were excluded from the
study because of graft failure, persistent disease, and
treatment-related death, and 386 patients relapsed by day
100. Among relapsed patients, 262 patients (68%) had
advanced disease, and this proportion is signiﬁcantly higher
than the proportion of patients with advanced diseases in
the entire cohort (31%). Thus, it is considered that early dis-
ease relapse before day 100 after transplantation is greatly
inﬂuenced by pretransplantation factors, and the role of CMV
reactivation in the protective effect from relapse could be
further clariﬁed by limiting the analysis to day-100 survivors
without relapse. Collectively, we included only the patients
who survived without disease relapse at day 100 in this
analysis. Our data clearly indicate that early CMV reac-
tivation, most of which developed before day 100, was
associated with a decreased incidence of relapse at 5 years
after transplantation. In multivariate analysis, the frequency
of CMV reactivation was affected by pretransplantation CMV
serostatus and the development of acute GVHD grades II to
IV. Although CMV reactivation in most of the patients fol-
lowed the development of acute GVHD grades II to IV,
multivariate analysis using time-dependent functions for the
development of acute and/or chronic GVHD and CMV reac-
tivation conﬁrmed that CMV reactivation was an indepen-
dent protective factor with regard to the risk of relapse
besides the development of chronic GVHD.
Several studies have already addressed the impact of
post-transplantation CMV reactivation on the risk of myeloid
malignancy relapse. Elmaagacli et al. [16] ﬁrst suggested a
clear beneﬁcial impact of early CMV reactivation on the 10-
year relapse incidence and 10-year OS in adult patientswith AML. Their cohort included 226 adult patients with
AML who received transplants from high-resolution HLA-
matched siblings or unrelated donors after MA conditioning
regimens, indicating that it was a homogeneous population.
In contrast, unlike the cohort of Elmaagacli et al., our cohort
was large but more heterogeneous, and we included patients
who received both MA and nonmyeloablative pre-
transplantation conditioning regimens and various types of
GVHD prophylaxis. However, our data additionally showed a
CMV reactivationeassociated protective effect on the 5-year
relapse incidence in the patients with AML and in the com-
bined cohort. Furthermore, the Seattle group [17] investi-
gated the prognostic impact of CMV reactivation using a
large heterogeneous cohort including patients with AML,
ALL, CML, MDS, and lymphoma, which is similar to our
cohort. However, these authors observed a much less bene-
ﬁcial effect of CMV reactivation on the risk of relapse. Their
analysis differs from ours in showing that CMV reactivation
was associated with a decreased risk of relapse by day 100,
but not by 1 year, among patients with AML, showing only a
modest relapse protection. The reason for these differences is
unclear, but their cohort included pediatric patients and
patients receiving transplants from HLA-mismatched do-
nors. A recent analysis of pediatric patients showed that, in
contrast to adult AML, CMV reactivation was associated with
an increased risk of relapse in pediatric patients with AML
[21]. In addition, relapse incidence and NRM are affected by
the degree of HLA compatibility [31,32]. Thus, these factors
may reduce the protective effect of CMV reactivation from
relapse in the cohort of the Seattle group. Nevertheless,
another recent retrospective analysis involving adult pa-
tients with AML from South Korea [19] and from St. Louis
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beneﬁcial effect of CMV reactivation on relapse is consistent,
at least in patients with AML. This CMV reac-
tivationeassociated protective effect was enriched in pa-
tients with advanced-risk disease, although this effect was
observed in both patients with standard-risk and advanced-
risk disease. However, we were unable to identify any
association between this effect and any speciﬁc AML sub-
populations, such as morphological and genetic subtypes
(data not shown). This could be because we did not have
sufﬁcient statistical power to detect differences in subpop-
ulation analyses. Regarding disease subgroups other than
AML, we observed a modest reduction in the incidence of
relapse in patients with MDS, although this did not reach
statistical signiﬁcance in multivariate analysis. Furthermore,
this did not differ signiﬁcantly with regard to morphological
subtypes and the risk category of MDS (data not shown).
CMV reactivation was not associated with relapse protection
in patients with ALL and CML; these data are in agreement
with those of the Seattle group [17]. Moreover, a recent
retrospective study conducted in Italy [20] showed that CMV
reactivation was not associated with the risk of relapse in
patients with B cell lymphoma after allo-HSCT, supporting
the ﬁndings of the Seattle group [17]. Ito et al. [18] reported a
protective effect of CMV reactivation in patients with CML.
However, in their cohort, the majority of the patients
received ex vivo T celledepleted grafts, and the relapse
incidence was relatively high (49%) compared with other
studies (10% to 15%) [16,17,19,21]. CMV reactivation may
show a protective effect in such a speciﬁc situation in pa-
tients with CML. With regard to these ﬁndings, CMV reac-
tivationeassociated relapse protection may be restricted to
patients with AML among various disease subgroups. How-
ever, very recent unpublished data regarding 11,153 patients,
including 5310 AML patients from Center for International
Blood and Marrow Transplant Research, indicated that early
CMV reactivation did not prevent relapse in patients with
AML after transplantation [33]. The previous reports,
including our study, are all retrospective studies. Thus, the
CMV-associated protective effect should be conﬁrmed by
meta-analysis and/or prospective observational studies.
Pretransplantation recipient and/or donor CMV seropos-
itivity was an independent risk factor for post-
transplantation CMV reactivation, and CMV reactivation
decreased the risk of relapse in the combined cohort and in
patients with AML. However, paradoxically, pre-
transplantation CMV seropositivity was an independent risk
factor for relapse in the combined cohort without any in-
crease in overall mortality. This interesting ﬁnding was also
reported by the Seattle group [17]. A large retrospective
study from the European Bone Marrow Transplant Working
Group [15], comprising 16,628 patients with AML or ALL,
reported that CMV seropositivity (R-CMVþ and/or D-CMVþ)
decreased OS because of the increased incidence of relapse
and NRM in patients with ALL, but not in patients with AML
in the European Bone Marrow Transplant cohort. Consistent
with the results of the Seattle group [17], there was a trend
toward an increased protective effect with regard to relapse
in CMV-seropositive (R-CMVþ and/or D-CMVþ) trans-
plantations with CMV reactivation compared with CMV-
seronegative (R-CMV/D-CMV) transplantations with CMV
reactivation. This could be 1 of the reasons underlying the
discrepancy between CMV serostatus and the increased
incidence of relapse.The underlying biological mechanism of CMV-associated
relapse reduction remains unknown. Thomson et al. [34]
found no association between CMV reactivation and
relapse incidence in patients with AML receiving
T celledepleted grafts along with alemtuzumab and no
protection from relapse by CMV-speciﬁc T cell infusion after
allo-HSCT, indicating that CMV-associated relapse protection
is mediated through an enhanced graft-versus-leukemia ef-
fect by a T or natural killer (NK) cell immune response, not
directly through CMV.Moreover, a recent report showed that
post-transplantation CMV reactivation induces a long-lasting
expansion of NKG2Cþ cells, which have a potent enhanced
anti-leukemia response by producing interferon-gamma
[35,36]. NKG2Cþ cells induced by CMV reactivation could
be a major mediator for reduction of the incidence of relapse.
In general, the NK cellemediated graft-versus-leukemia ef-
fect is more prominent in myeloid malignancies than in
lymphoid malignancies [37-39], and this could be the reason
why a CMV-associated decreased incidence of relapse was
observed mainly in patients with AML. An alternative
hypothesis is that this effect may be mediated by GCV-
mediated myelosuppression. We did not observe any sig-
niﬁcant difference in the duration of preemptive therapy
between relapsed and nonrelapsed patients, indicating that
the degree of neutropenia was comparable between the 2
groups. Thus, we consider that GCV-mediated cytotoxicity
was not involved in the reduced risk of relapse in patients
with CMV reactivation.
Despite the decreased risk of relapse in patients with
AML, we were unable to correlate CMV reactivation with
improved OS, which was related to the increased NRM with
CMV reactivation. This result differs from observations of
Elmaagacli et al. [16] who showed improved OS in patients
with AML. In contrast, in our cohort, CMV reactivationwas an
independent risk factor for NRM in the combined cohort and
in patients with AML, ALL, and for overall mortality in the
combined cohort and in patients with AML. This increased
NRM with CMV reactivation was reported by the Seattle
group [17] and the St. Louis group [22]. Although information
regarding the cause of death was limited in our registry data,
there were no signiﬁcant differences between the 2 groups
except for disease relapse and acute GVHD (data not shown),
and the speciﬁc reasons for higher NRM among patients with
CMV reactivation were unclear. These ﬁndings indicate that
current strategies for managing CMV infection by antiviral
drugs may not be sufﬁcient to translate the efﬁcacy of CMV
reactivation into improved OS, and new therapies that can
induce immunological response but not increase NRM are
required. Recently, the clinical efﬁcacy of a CMV-therapeutic
DNA vaccine against CMV surface glycoprotein B and pp65
was reported in a phase 2 clinical trial [40], and this could be
a treatment option.
In conclusion, our ﬁndings indicate that post-
transplantation CMV reactivation can reduce the risk of
relapse in patients with AML who survive until day 100 after
transplantation. However, this beneﬁcial effect could not be
correlated with improved OS because of increased NRM. This
protective effect for relapse should be conﬁrmed by large
prospective observational studies and the mechanism
responsible for this protective effect induced by CMV reac-
tivation requires elucidation. A better understanding of this
mechanism could be of great help in developing a novel CMV
antigenerelated vaccination therapy aimed at reducing both
the posteallo-HSCT relapse risk and NRM in the future.
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